Skip to main content

Table 5 Cox model on risk associations with being a SARS-CoV-2 incident case in study participants.a

From: SARSCoV-2 antibody prevalence and titers in persons living with HIV cared for at a large tertiary reference center in Mexico City

  

HR

 

95% CI

 

p value

aHR

 

95% CI

 

p value

Age (years)

 

0.99

0.97

–

1.00

0.148

1.00

0.98

–

1.03

0.572

Vaccinated against COVID-19

No

  

Ref

    

Ref

  

Yes

0.9

0.6

–

1.4

0.657

1.2

0.7

–

1.9

0.553

Municipality

South Mexico City

Ref

    

Ref

  

North Mexico City

1.3

0.6

–

2.4

0.505

1.3

0.6

–

2.8

0.440

East Mexico City

1.6

0.9

–

2.9

0.079

1.9

1.0

–

3.5

0.045

West Mexico City

1.4

0.8

–

2.3

0.237

1.6

0.9

–

2.8

0.105

State of Mexico

1.2

0.7

–

2.0

0.575

1.3

0.7

–

2.2

0.435

Otherb

1.0

0.5

–

2.0

0.954

0.8

0.4

–

1.7

0.553

Comorbiditiesc

No

  

Ref

    

Ref

  

Yes

1.0

0.6

–

1.5

0.889

0.9

0.6

–

1.4

0.697

Meetings without social distancing

No

  

Ref

    

Ref

  

Yes

1.1

0.7

–

1.5

0.756

1.1

0.7

–

1.6

0.728

Use of public transport

No

  

Ref

    

Ref

  

Subway

1.0

0.7

–

1.4

0.948

0.8

0.5

-

1.2

0.279

Taxi/Uber

0.8

0.3

–

2.3

0.702

0.8

0.3

–

2.4

0.702

Otherd

1.3

0.8

–

2.3

0.285

1.1

0.6

–

2.1

0.657

Type of COVID-19 vaccine

Non-vaccinated

 

Ref

    

Ref

  

BTN162b2 (Pfizer/BioNTech)

0.4

0.2

–

0.8

0.005

0.4

0.2

–

0.8

0.013

AZD1222 (AstraZeneca)

1.0

0.6

–

1.4

0.866

1.0

0.6

–

1.6

0.858

Ad5-nCoV (CanSino)

1.4

0.6

–

3.1

0.380

1.7

0.7

–

4.0

0.239

Gam-COVID-Vac (Sputnik-V)

0.7

0.4

–

1.6

0.432

0.6

0.3

–

1.5

0.280

CoronaVac (Sinovac)

1.3

0.5

–

3.6

0.622

1.2

0.4

–

3.7

0.805

CD4 category (cells/mm3)e

 < 200

  

Ref

    

Ref

  

200–499

0.9

0.5

–

1.8

0.813

0.9

0.5

–

1.8

0.798

 ≥ 500

1.0

0.5

–

2.0

0.968

1.1

0.5

–

2.5

0.727

CD4:CD8 ratioe

 

0.9

0.6

–

1.4

0.653

0.9

0.5

–

1.6

0.732

Time with suppressed VL (years)

 

1.0

0.9

–

1.0

0.319

1.0

0.9

–

1.0

0.436

  1. HR crude hazard ratio, aHR adjusted hazard ratio, CI confidence interval, Ref. reference, VL viral load. Statistically significant P values (≤ 0.05) are in bold
  2. aPrevalent cases (n = 233) were excluded from the model
  3. bIncludes municipalities in other states; c Includes arterial hypertension, diabetes mellitus, asthma, chronic obstructive pulmonary disease, overweight/obesity, cardiovascular diseases, tuberculosis, liver, kidney and autoimmune diseasesdIncludes bus rapid transit (metrobus), bus, minibus and trolleybus
  4. eFrom the last available blood sample
Back to article page

Virology Journal

ISSN: 1743-422X